Zealand Pharma AS

22Z

Company Profile

  • Business description

    Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

  • Contact

    Sydmarken 11
    SoborgDK-2860
    DNK

    T: +45 88773600

    E: [email protected]

    https://www.zealandpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    393

Stocks News & Analysis

stocks

Are small caps finally back?

Does renewed investor interest point to a structural shift in the underperforming factor?
stocks

Chart of the Week: Modest earnings growth at odds with overvalued bank shares

The latest update from our Industry Pulse report.
stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,329.1050.900.55%
CAC 408,225.7818.910.23%
DAX 4024,207.7956.660.23%
Dow JONES (US)46,759.58169.170.36%
FTSE 1009,578.5763.570.67%
HKSE25,967.98186.210.72%
NASDAQ22,965.46225.070.99%
Nikkei 22548,641.61666.18-1.35%
NZX 50 Index13,377.1070.660.53%
S&P 5006,744.1244.720.67%
S&P/ASX 2009,032.8046.600.52%
SSE Composite Index3,922.418.650.22%

Market Movers